US20080207582A1 - Substituted Porphyrins - Google Patents
Substituted Porphyrins Download PDFInfo
- Publication number
- US20080207582A1 US20080207582A1 US12/025,612 US2561208A US2008207582A1 US 20080207582 A1 US20080207582 A1 US 20080207582A1 US 2561208 A US2561208 A US 2561208A US 2008207582 A1 US2008207582 A1 US 2008207582A1
- Authority
- US
- United States
- Prior art keywords
- iii
- porphyrins
- pyp
- methyl
- increase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1=C(*)/C2=C(\C3=CC=CC=[N+]3*)C3=C(*)C(*)=C(N3)/C(C3=CC=CC=[N+]3*)=C3\N=C(C(/*)=C\3*)\C(C3=CC=CC=[N+]3*)=C3/N/C(=C(/C4=CC=CC=[N+]4*)C1=N2)C(*)=C3*.*C1=C(*)/C2=C(\C3=CC=CC=[N+]3*)C3=N4/C(=C(/C5=CC=CC=[N+]5*)C5=C(*)C(*)=C6/C(C7=CC=CC=[N+]7*)=C7C(/*)=C(/*)C8=N/7C4(N56)N2C1=C8C1=CC=CC=[N+]1*)C(*)=C3*.*C1=C(*)/C2=C(\C3=CC=C[N+](*)=C3)C3=N4/C(=C(/C5=C[N+](*)=CC=C5)C5=C(*)C(*)=C6/C(C7=CC=C[N+](*)=C7)=C7C(/*)=C(/*)C8=N/7C4(N56)N2C1=C8C1=C[N+](*)=CC=C1)C(*)=C3* Chemical compound *C1=C(*)/C2=C(\C3=CC=CC=[N+]3*)C3=C(*)C(*)=C(N3)/C(C3=CC=CC=[N+]3*)=C3\N=C(C(/*)=C\3*)\C(C3=CC=CC=[N+]3*)=C3/N/C(=C(/C4=CC=CC=[N+]4*)C1=N2)C(*)=C3*.*C1=C(*)/C2=C(\C3=CC=CC=[N+]3*)C3=N4/C(=C(/C5=CC=CC=[N+]5*)C5=C(*)C(*)=C6/C(C7=CC=CC=[N+]7*)=C7C(/*)=C(/*)C8=N/7C4(N56)N2C1=C8C1=CC=CC=[N+]1*)C(*)=C3*.*C1=C(*)/C2=C(\C3=CC=C[N+](*)=C3)C3=N4/C(=C(/C5=C[N+](*)=CC=C5)C5=C(*)C(*)=C6/C(C7=CC=C[N+](*)=C7)=C7C(/*)=C(/*)C8=N/7C4(N56)N2C1=C8C1=C[N+](*)=CC=C1)C(*)=C3* 0.000 description 6
- TWDGASLCYYZUTM-UHFFFAOYSA-P C.C.C.C.[H+].[H+].[PH6+3].[PH7+4].[PH7+4].[PH8+5] Chemical compound C.C.C.C.[H+].[H+].[PH6+3].[PH7+4].[PH7+4].[PH8+5] TWDGASLCYYZUTM-UHFFFAOYSA-P 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- Mn(III) meso tetrakis(N-methylpyridinium-2-yl)porphyrin Mn III TM-2-PyP 5+ , AEOL-10112
- Mn III TE-2-PyP 5+ , AEOL-11013 meso tetrakis(N-ethylpyridinium-2-yl)porphyrins
- FIG. 1 Structures of the most hydrophilic (Mn III TM2-PyP 5+ ) and the most lipophilic (Mn III TnOct2-PyP 5+ ) members of the series studied. The ⁇ atropoisomers are shown.
- FIG. 2 The lipophilicity, R f of H 2 T(alkyl)-2-PyP 4+ (A) and Mn III T(alkyl)-2-PyP 5+ compounds (B) vs the number of CH 2 groups.
- FIG. 3 Proton dissociation constants pK a2 of the metal-free porphyrins, H 2 T(alkyl)-2-PyP 4+ (A), and the metal-centered redox potentials E 1/2 for the Mn(III)/Mn(II) couple of Mn III T(alkyl)-2-PyP 5+ porphyrins (B) as a function of R f . Inserts: pK a2 ( FIG. 3A ) and E 1/2 ( FIG. 3B ) vs the number of CH 2 groups.
- FIG. 4 The reactivity of water-soluble Mn(III) porphyrins (A) (ref 4) and Mn III T(alkyl)-2-PyP 5+ porphyrins (B) as catalysts for O 2 ⁇ dismutation, expressed in terms of log k cat vs E 1/2 .
- FIG. 5 E 1/2 for the Mn(III)/Mn(II) couple of Mn III T(alkyl)-2-PyP 5+ porphyrins vs pK a2 of the corresponding metal-free ligands.
- FIG. 6 Cyclic voltammetry of 0.5 mM Mn III TE-2-PyP 5+ and Mn III TnHex-2-PyP 5+ porphyrins in a 0.05 M phosphate buffer (pH 7.8, 0.1 M NaCl) at a scan rate of 0.1 V/s.
- FIG. 7 Electrospray mass spectrometry of 0.5 mM solutions of H 2 T(alkyl)-2-PyP 4+ compounds in 1:1 water:acetonitrile at a cone voltage of 20 V.
- FIG. 8 Electrospray mass spectrometry of 0.5 mM solutions of Mn III T(alkyl)-2-PyP 5+ compounds in 1:1 water:acetonitrile at a cone voltage of 20 V.
- FIG. 9 As the alkyl chains of Mn(III) porphyrins lengthen, the favorable increase in E 1/2 overcomes the unfavorable steri/electrostatic effects such that the n-octyl is as potent a catalyst of O 2 — dismutation as are the methyl and ethyl compounds.
- the present invention relates to a compound of formula
- each R is, independently, an C1-C12 alkyl (preferably, a C8 to C12 alkyl),
- each A is, independently, hydrogen or an electron withdrawing group
- M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc, and
- Z ⁇ is a counterion.
- at least one A is a halogen.
- the invention further relates to a method of protecting cells (eg mammalian cells) from oxidant-induced toxicity comprising contacting the cells with a protective amount of a compound as described above.
- the invention further relates to a method of treating a pathological condition of a patient resulting from oxidant-induced toxicity comprising administering to the patient an effective amount of such a compound.
- the invention also relates to a method of treating a pathological condition of a patient resulting from degradation of NO • , comprising administering to the patient an effective amount of a compound as described above.
- the invention relates to a method of treating a patient for inflammatory lung disease comprising administering to the patient an effective amount of a compound as described above.
- the inflammatory lung disease can be a hyper-reactive airway disease.
- the disease can be asthma.
- MnCl 2 ⁇ 4H 2 O, and Baker-flex silica gel IB TLC plates were purchased from J. T. Baker. N,N-dimethylformamide, ethyl p-toluenesulfonate, 2-propanol (99.5+%), NH 4 PF 6 (99.99%), NaCl, sodium L-ascorbate (99+%) and tetrabutylammonium chloride were from Aldrich, while xanthine, and ferricytochrome c were from Sigma.
- the n-propyl, n-butyl, n-hexyl and n-octyl esters of p-toluenesulfonic acid were from TCI America.
- Methanol (anhydrous, absolute), ethanol (absolute), acetone, ethyl ether (anhydrous), chloroform, EDTA and KNO 3 were from Mallinckrodt and acetonitrile was from Fisher Scientific.
- Xanthine oxidase was prepared by R. Wiley and was supplied by K. V. Rajagopalan. 18 Catalase was from Boehringer, ultrapure argon from National Welders Supply Co., and tris buffer (ultrapure) was from ICN Biomedicals, Inc.
- H 2 T(alkyl)-2-PyP 4+ Tetrakis(2-pyridyl)porphyrin, H 2 T-2-PyP was purchased from Mid-Century Chemicals, Chicago, Ill. The increased lipophilicity of the n-propyl, n-butyl, n-hexyl, and n-octyl analogues required a slight modification of the synthetic approach used for methyl and ethyl compounds. 4,12 Typically, 100 mg of H 2 T-2-PyP was dissolved in 20 mL of DMF at 100° C., followed by the addition of 4 mL of the corresponding p-toluenesulfonate.
- n-butyl, n-hexyl and n-octyl analogues are more lipophilic and tended to remain in the chloroform layer. Therefore, increasing amounts of methanol were added to the water/CHCl 3 mixture in order to force the porphyrin into the aqueous/methanol layer. This layer was filtered and the porphyrin was precipitated as the PF 6 ⁇ salt by the addition of a concentrated aqueous solution of NH 4 PF 6 . The precipitate was thoroughly washed with 1:1 2-propanol:diethylether in the case of methyl and ethyl compounds and with pure diethylether for the others.
- Mn(II) porphyrin The formation of the Mn(II) porphyrin and its oxidation to Mn(III) were clearly distinguishable steps when the n-hexyl and n-octyl analogues were metallated. As was the case with the metal-free ligands, the PF 6 ⁇ salts of Mn(III) n-propyl, n-butyl, n-hexyl and n-octyl compounds were washed only with diethylether. Elemental analysis: Mn III TnPr-2-PyPCl 5 ⁇ 11.5 H 2 O (MnC 52 H 75 N 8 O 11.5 Cl 5 ). Found: C, 50.90; H, 6.07; N, 9.27; Cl, 13.48.
- Electrochemistry Measurements were performed on a CH Instruments Model 600 Voltammetric Analyzer. 3,4 A three-electrode system in a small volume cell (0.5 mL to 3 mL), with a 3 mm-diameter glassy carbon button working electrode (Bioanalytical Systems), plus the Ag/AgCl reference and Pt auxillary electrodes was used. Solutions contained 0.05 M phosphate buffer, pH 7.8, 0.1 M NaCl, and 0.5 mM metalloporphyrin. The scan rates were 0.01-0.5 V/s, typically 0.1 V/s. The potentials were standardized against the potassium ferrocyanide/ferricyanide 20 and/or against Mn III TE-2-PyP 5+ . All voltammograms were reversible.
- Electrospray mass spectrometry Electrospray mass spectrometry. ESMS measurements were performed on a Micromass Quattro LC triple quadrupole mass spectrometer equipped with a pneumatically assisted electrostatic ion source operating at atmospheric pressure. Typically, the 0.5 mM 50% aqueous acetonitrile solutions of chloride salts of metal-free porphyrins or their Mn(III) complexes were introduced by loop injection into a stream of 50% aqueous acetonitrile flowing at 8 ⁇ L/min. Mass spectra were acquired in continuum mode, scanning from 100-500 m/z in 5 s, with cone voltages of 20 V and 24 V. The mass scale was calibrated using polyethylene glycol.
- the xanthine/xanthine oxidase reaction was the source of O 2 • ⁇ and ferricytochrome c was used as the indicating scavenger for O 2 • ⁇ 22
- the reduction of cytochrome c was followed at 550 nm.
- the O 2 • ⁇ was produced at the rate of 1.2 ⁇ M per minute. Any possible interference through inhibition of the xanthine/xanthine oxidase reaction by the test compounds was examined by following the rate of urate accumulation at 295 nm in the absence of cytochrome c. No reoxidation of cytochrome c by the metalloporphyrins was observed.
- K a2 and K a3 are defined as follows:
- FIG. 3A shows the linear relationship between pK a2 and R f .
- Equilibrium constants pK a3 for reaction [2] are 1.8 for the meta H 2 TM-3-PyP 4+ , 1.4 for the para H 2 TM-4-PyP 4+ , and ⁇ 0.9 for ortho H 2 TM-2-PyP 4+ . 4,25 While the meta and para N-methylpyridylporphyrins are mixtures of protonated H 3 P 5+ and H 4 P 6+ species in 1.0 M HCl, the ortho substituted H 2 TM-2-PyP 4+ to H 2 TnOct-2-PyP 4+ compounds remain as the unprotonated free base H 2 P 4+ in 1.0 M HCl and in 1.0 M HNO 3 . With ortho, meta and para N-methylpyridylporphyrins the pK a2 increases as the pK a3 increases.
- Mn(III) meso tetrakis ortho N-alkylpyridylporphyrins in vivo will be readily reduced with cell reductants such as ascorbic acid. 2,3,12
- the reduced Mn(II) porphyrins will also be transiently formed in the catalysis of O 2 • ⁇ dismutation. Therefore, we also examined the behavior of the reduced and more biologically relevant Mn III T(alkyl)-2-PyP 4+ compounds.
- Electrospray mass spectrometry The ESMS proved to be a valuable tool for accessing the properties of the free base porphyrins and their Mn complexes whereby the impact of structure on solvation, ion-pairing, redox properties, protonation/deprotonation, dealkylation, and catalytic properties are clearly depicted.
- H 2 T(alkyl)-2-PyP 4+ The ESMS of the metal-free porphyrins obtained at the low cone voltage of 20 V showed dominant molecular ions assigned to H 2 P 4+ /4 and/or its mono-deprotonated analogue, H 2 P 4+ ⁇ H + /3 (Table 3, FIG. 7 ). Negligible double deprotonation (H 2 P 4+ ⁇ 2H+/2) was noted. Only H 2 TM-2-PyP 4+ gave rise to a high-intensity H 2 P 4+ +H + /5 peak.
- the ESMS shows a pronounced decrease in solvation by acetonitrile as the alkyl chains lengthen.
- the relative intensities of the mono-solvated molecular ions range from 40% for methyl, 15% for ethyl, and ⁇ 10% for the higher analogues. Only with the n-hexyl and n-octyl porphyrins are small peaks ( ⁇ 5%) from ions associated with chloride found.
- the ratio of the molecular ion to mono-deprotonated ion peaks decreases, consistent with the trend in pK a2 .
- the base peak for methyl is that of the molecular ion
- the base peak for the n-propyl and n-butyl porphyrins is the mono-deprotonated ion.
- This pK a2 trend is overcome by the higher lipophilicities of the n-hexyl and n-octyl compounds, where roughly equal-intensity molecular ion (100%) and mono-deprotonated ion (98%) peaks are observed.
- Mn III T(alkyl)-2-PyP 5+ The ESMS of the Mn(III) complexes was done at a lower cone voltage (20 V) than in our previous study (30-58 V). 37 Therefore, less fragmentation occurs and more solvent-associated and ion-paired species could be observed (Table 4, FIG. 8 ). Solvation and ion pairing are more pronounced when compared with the metal-free ligands. The more lipophilic Mn(III) porphyrins are more easily desolvated in the electrospray ionization source. In accordance with our previous observations, the ESMS also clearly reflects the redox properties of these compounds. 37,38 The higher the E 1/2 the more reduced porphyrins are noted. Species solvated with acetonitrile or associated with chloride were observed with both Mn(III) and Mn(II) compounds. Two chlorides were associated only with Mn(III) porphyrins.
- the ESMS behavior of Mn porphyrins changes sharply once the alkyl chains lengthen beyond butyl, as observed with corresponding metal-free analogues. No loss of methyl groups was detected. 37 As the chains lengthen up to butyl the loss of an alkyl group from Mn(III) and Mn(II) porphyrins becomes more pronounced and then the tendency decreases with n-hexyl and n-octyl. The same trend, but of lower intensity was noted for the loss of two alkyl groups. The ratio of mono-chlorinated Mn(III) to mono-chlorinated Mn(II) species decreases from methyl to n-butyl and then increases up to n-octyl.
- the base peak of the methyl and ethyl porphyrins relates to Mn III P 5+ +Cl ⁇ /4, while for the n-propyl and n-butyl derivatives it relates to Mn III P 4+ +Cl ⁇ /3. Yet, with the n-hexyl, the Mn III P 5+ +Cl ⁇ /4 and Mn II P 4+ +Cl ⁇ /3 peaks are both of 100% intensity, and the di-chlorinated species (Mn III P 5+ +2Cl ⁇ /3) is of 86% intensity.
- the mono- and di-chlorinated species give rise to 100% Mn III P 5+ Cl ⁇ /4 and 89% Mn III P 5+ +2Cl ⁇ /3peaks, and the third most intense (59%) signal relates to Mn II P 4+ +Cl ⁇ /3.
- the base peak of ortho MnTM-2-PyP 5+ is the mono-chlorinated species, which was only 35% for para isomer.
- k cat may also be influenced by the electrostatic/steric effects originating from the shielding of the single positive charge on the Mn(III) center.
- the difference in the magnitude of lipophilicity between the metal-free ligands (formally +4) and the Mn(III) complexes (formally +5) becomes less noticeable as the alkyl chains get longer (Table 1).
- These H 2 P 4+ compounds of formal +4 charge behave in solution kinetically as +1.6 to +1.8 electrolytes.
- log k cat decreases almost linearly ( FIG. 4B , insert). Due to the exponential increase in E 1/2 along the series of Mn porphyrins ( FIG.
- the unfavorable electrostatic/steric effects are in part opposed and finally overcome by the progressively more favorable redox potentials that originate from increased desolvation (lipophilicity). Consequently, the very lipophilic n-octyl compound is essentially as potent an SOD mimic as the less lipophilic methyl and ethyl derivatives.
- Regan et al 47 were able to uncouple the steric and solvation effects in reactions of chloride ions with methyl- and tert-butyl-substituted chloroacetonitrile, and showed that both were of comparable magnitudes.
- the reactivity of N-alkylpyridylporphyrins are the result of the interplay of electronic, steric and solvation effects, the latter dominating with the more lipophilic members of the series.
- Mn III T(alkyl)-2(3,4)-PyP 5+ manganese(III) meso tetrakis(N-methyl, N-ethyl, N-n-propyl, N-n-butyl, N-n-hexyl, N-n-octyl)pyridinium-2(3,4)-yl)porphyrin; alkyl is M, methyl; E, ethyl; nPr, n-propyl; nBu, n-butyl; nHex, n-hexyl; nOct, n-octyl on the pyridyl ring; 2 is the ortho, 3, the meta and 4 the para isomer; Mn III TM-2-PyP 5+ is AEOL-10112, and Mn III TE-2-PyP 5+ is AEOL-10113; Mn III PTr(M-2-PyP 4+ , manganese
- R f for the metal-free porphyrins are in parentheses.
- b pK a2 determined at 25° C. ionic strength 0.10 (NaNO 3 /NaOH).
- c E 1/2 determined in 0.05 M phosphate buffer (pH 7.8, 0.1 M NaCl).
- d k cat determined using the cytochrome c assay, in 0.05 M phosphate buffer, pH 7.8, at (25 ⁇ 1) ° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A series of ortho isomers of meso tetrakis N-alkylpyridylporphyrins (alkyl being methyl, ethyl, n-propyl, n-butyl, n-hexyl, and n-octyl) and their Mn(III) complexes were synthesized and characterized by elemental analysis, uv/vis spectroscopy, electrospray ionization mass spectrometry and electrochemistry. An increase in the number of carbon atoms in the alkyl chains from 1 to 8 is accompanied by an increase in: (a) lipophilicity measured by the chromatographic retention factor, Rf; (b) metal-centered redox potential, E1/2 from +220 to +367 mV vs NHE, and (c) proton dissociation constant, pKa2 from 10.9 to 13.2. A linear correlation was found between E1/2 and Rf of the Mn(III) porphyrins and between the pKa2 and Rf of the metal-free compounds. As the porphyrins become increasingly more lipophilic, the decrease in hydration disfavors the separation of charges, while enhancing the electron-withdrawing effect of the positively charged pyridyl nitrogen atoms. Consequently, the E1/2 increases linearly with the increase in pKa2, a trend in porphyrin basicity opposite from the one we previously reported for other water-soluble Mn(III) porphyrins. All of these Mn(III) porphyrins are potent catalysts for superoxide dismutation (disproportionation). Despite the favorable increase of E1/2 with the increase in chain length, the catalytic rate constant decreases from methyl (log kcat=7.79) to n-butyl, and then increases such that the n-octyl is as potent an SOD mimic as are the methyl and ethyl compounds. The observed behavior originates from an interplay of hydration and steric effects that modulate electronic effects.
Description
- This application is a divisional of patent application Ser. No. 10/456,956, filed Jun. 9, 2003 which claims priority from Provisional Application No. 60/386,454, filed Jun. 7, 2002, the content of which is incorporated herein by reference.
- Low-molecular weight catalytic scavengers of reactive oxygen and nitrogen species, aimed at treating oxidative stress injuries, have been actively sought. Three major groups of manganese complexes have been developed and tested in vitro and in vivo; Mn porphyrins,1-9 Mn cyclic polyamines10 and Mn salen derivatives.11 Based on a structure-activity relationships that we developed for water-soluble Mn(III) and Fe(III) porphyrins,2-4 Mn(III) meso tetrakis(N-methylpyridinium-2-yl)porphyrin (MnIIITM-2-PyP5+, AEOL-10112) and meso tetrakis(N-ethylpyridinium-2-yl)porphyrins (MnIIITE-2-PyP5+, AEOL-11013) were proposed and then shown to be potent catalysts for superoxide dismutation.4,12 The alkyl substitutions at the ortho positions restrict the rotation of the pyridyl rings with respect to the porphyrin plane. Consequently both compounds exist as mixtures of four atropoisomers, all of which were shown to be equally potent catalysts for O2 •− dismutation.13 These Mn porphyrins also allow SOD-deficient Escherichia coli to grow under aerobic conditions,4,12 and offer protection in rodent models of oxidative stress such as stroke,14 diabetes,15 sickle cell disease,16 and cancer/radiation.17 The high formal +5 charge of these metalloporphyrins could influence their tissue distribution, transport across biological membranes, and binding to other biomolecules and their low lipophilicities may restrict their protective effects. With the aim of modulating metalloporphyrin subcellular distribution, higher N-alkylpyridylporphyrin analogues (Scheme I) with increased lipophilicity were synthesized. We anticipate that their comparative kinetic and thermodynamic characterization will deepen our insight into the modes of action of porphyrin-based catalytic antioxidants and the mechanisms of oxidative stress injuries.
-
FIG. 1 . Structures of the most hydrophilic (MnIIITM2-PyP5+) and the most lipophilic (MnIIITnOct2-PyP5+) members of the series studied. The αβαβ atropoisomers are shown. -
FIG. 2 . The lipophilicity, Rf of H2T(alkyl)-2-PyP4+ (A) and MnIIIT(alkyl)-2-PyP5+ compounds (B) vs the number of CH2 groups. -
FIG. 3 . Proton dissociation constants pKa2 of the metal-free porphyrins, H2T(alkyl)-2-PyP4+ (A), and the metal-centered redox potentials E1/2 for the Mn(III)/Mn(II) couple of MnIIIT(alkyl)-2-PyP5+ porphyrins (B) as a function of Rf. Inserts: pKa2 (FIG. 3A ) and E1/2 (FIG. 3B ) vs the number of CH2 groups. -
FIG. 4 . The reactivity of water-soluble Mn(III) porphyrins (A) (ref 4) and MnIIIT(alkyl)-2-PyP5+ porphyrins (B) as catalysts for O2 − dismutation, expressed in terms of log kcat vs E1/2. -
FIG. 5 . E1/2 for the Mn(III)/Mn(II) couple of MnIIIT(alkyl)-2-PyP5+ porphyrins vs pKa2 of the corresponding metal-free ligands. Insert: E1/2 of water-soluble Mn(III) porphyrins vs pKa3 (data from ref 4); MnIIITE-2-PyP5+ (1), MnTM-2-PyP5+ (2), MnPTrM-2-PyP4+ (3), MnIIITM-4-PyP5+ (4), MnIIITM-3-PyP5+ (5), MnIIIT(2,6-Cl2-3-SO3—P)P−3 (6), MnIIIT(TFTMA)P5+ (7), MnIIIT(αααα-2-MINP)P5+ (8), MnIIIT(2,6-Cl2-3-SO3—P)P3− (9), MnIIIT(2,4,6-Me3-3,5-(SO3)2—P)P7− (10), MnIII(TMA)P5+ (11), MnTSPP3− (12), MnTCPP3− (13), MnIIIhematoP− (14). -
FIG. 6 . Cyclic voltammetry of 0.5 mM MnIIITE-2-PyP5+ and MnIIITnHex-2-PyP5+ porphyrins in a 0.05 M phosphate buffer (pH 7.8, 0.1 M NaCl) at a scan rate of 0.1 V/s. -
FIG. 7 . Electrospray mass spectrometry of 0.5 mM solutions of H2T(alkyl)-2-PyP4+ compounds in 1:1 water:acetonitrile at a cone voltage of 20 V. -
FIG. 8 . Electrospray mass spectrometry of 0.5 mM solutions of MnIIIT(alkyl)-2-PyP5+ compounds in 1:1 water:acetonitrile at a cone voltage of 20 V. -
FIG. 9 . As the alkyl chains of Mn(III) porphyrins lengthen, the favorable increase in E1/2 overcomes the unfavorable steri/electrostatic effects such that the n-octyl is as potent a catalyst of O2— dismutation as are the methyl and ethyl compounds. - The present invention relates to a compound of formula
- wherein
- each R is, independently, an C1-C12 alkyl (preferably, a C8 to C12 alkyl),
- each A is, independently, hydrogen or an electron withdrawing group,
- M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc, and
- Z− is a counterion. In one embodiment, at least one A is a halogen.
- The invention further relates to a method of protecting cells (eg mammalian cells) from oxidant-induced toxicity comprising contacting the cells with a protective amount of a compound as described above. The invention further relates to a method of treating a pathological condition of a patient resulting from oxidant-induced toxicity comprising administering to the patient an effective amount of such a compound. The invention also relates to a method of treating a pathological condition of a patient resulting from degradation of NO•, comprising administering to the patient an effective amount of a compound as described above. Additionally, the invention relates to a method of treating a patient for inflammatory lung disease comprising administering to the patient an effective amount of a compound as described above. The inflammatory lung disease can be a hyper-reactive airway disease. The disease can be asthma.
- The entire content of all documents cited herein are incorporated herein by reference. Also incorporated herein by reference is Batinic-Haberle et al, J. Chem. Soc., Dalton Trans. 2002, 2689-2696.
- Also incorporated by reference is U.S. application Ser. No. 09/880,125, filed Jun. 14, 2001.
- General. MnCl2×4H2O, and Baker-flex silica gel IB TLC plates were purchased from J. T. Baker. N,N-dimethylformamide, ethyl p-toluenesulfonate, 2-propanol (99.5+%), NH4 PF6 (99.99%), NaCl, sodium L-ascorbate (99+%) and tetrabutylammonium chloride were from Aldrich, while xanthine, and ferricytochrome c were from Sigma. The n-propyl, n-butyl, n-hexyl and n-octyl esters of p-toluenesulfonic acid were from TCI America. Methanol (anhydrous, absolute), ethanol (absolute), acetone, ethyl ether (anhydrous), chloroform, EDTA and KNO3 were from Mallinckrodt and acetonitrile was from Fisher Scientific. Xanthine oxidase was prepared by R. Wiley and was supplied by K. V. Rajagopalan.18 Catalase was from Boehringer, ultrapure argon from National Welders Supply Co., and tris buffer (ultrapure) was from ICN Biomedicals, Inc.
- H2T(alkyl)-2-PyP4+. Tetrakis(2-pyridyl)porphyrin, H2T-2-PyP was purchased from Mid-Century Chemicals, Chicago, Ill. The increased lipophilicity of the n-propyl, n-butyl, n-hexyl, and n-octyl analogues required a slight modification of the synthetic approach used for methyl and ethyl compounds.4,12 Typically, 100 mg of H2T-2-PyP was dissolved in 20 mL of DMF at 100° C., followed by the addition of 4 mL of the corresponding p-toluenesulfonate. The course of N-alkylation was followed by thin-layer chromatography on silica gel TLC plates using 1:1:8 KNO3-saturated H2O:H2O:acetonitrile as a mobile phase. While complete N-alkylation is achieved within a few hours for the methyl analogue, the required time gradually increases and it took three and five days to prepare the n-hexyl and n-octyl compounds, respectively. Upon completion, for the methyl, ethyl and n-propyl compounds, the reaction mixture was poured into a separatory funnel containing 200 mL each of water and chloroform and shaken well. The chloroform layer was discarded and the extraction with CHCl3 was repeated several times. The n-butyl, n-hexyl and n-octyl analogues are more lipophilic and tended to remain in the chloroform layer. Therefore, increasing amounts of methanol were added to the water/CHCl3 mixture in order to force the porphyrin into the aqueous/methanol layer. This layer was filtered and the porphyrin was precipitated as the PF6 − salt by the addition of a concentrated aqueous solution of NH4 PF6. The precipitate was thoroughly washed with 1:1 2-propanol:diethylether in the case of methyl and ethyl compounds and with pure diethylether for the others. The precipitate was then dissolved in acetone, filtered and precipitated as the chloride salt by the addition of tetrabutylammonium chloride dissolved in acetone. The precipitate was washed thoroughly with acetone, and dried in vacuo at room temperature. Elemental analysis: H2TnPr-2-PyPCl4×12.5H2O (C52H71N8O12.5Cl4). Found: C, 54.2; H, 6.42; N, 9.91; Cl, 12.04. Calculated: C, 54.20; H, 6.18; N, 9.68; Cl, 12.25. H2TnBut-2-PyPCl4×10.5 H2O(C56H75N8O10.5Cl4). Found: C, 57.16; H, 6.94; N, 9.513; Cl, 1.77. Calculated: C, 57.10; H, 6.41; N, 9.51; Cl, 12.03. H2TnHex-2-PyPCl4×11 H2O (C64H100N8O11Cl4). Found: C, 59.19; H, 7.31; N, 8.61; Cl, 11.09. Calculated: C, 59.16; H, 7.751; N, 8.60; Cl, 10.91. H2TnOct-2-PyPCl4×13.5H2O (C64H121N8O13.5Cl4). Found: C, 59.37; H, 7.41; N, 7.73. Calculated: C, 59.37; H, 8.37; N, 7.69.
- MnIIIT(alkyl)-2-PyP5+. Metalation of the N-alkylated porphyrins was achieved as described previously for the methyl and ethyl compounds.4,12 Metal incorporation became slower as the alkyl chains lengthened. Under same conditions (20-fold excess metal, 25° C., pH 12.3) it occurs almost instantaneously for methyl and ethyl, within minutes for n-propyl, in ˜30 minutes for n-butyl, in ˜1 hour with the n-hexyl, and took several hours at 100° C. for the n-octyl porphyrin. The formation of the Mn(II) porphyrin and its oxidation to Mn(III) were clearly distinguishable steps when the n-hexyl and n-octyl analogues were metallated. As was the case with the metal-free ligands, the PF6 − salts of Mn(III) n-propyl, n-butyl, n-hexyl and n-octyl compounds were washed only with diethylether. Elemental analysis: MnIIITnPr-2-PyPCl5×11.5 H2O (MnC52H75N8O11.5Cl5). Found: C, 50.90; H, 6.07; N, 9.27; Cl, 13.48. Calculated: C, 50.85; H, 6.16; N, 9.12; Cl, 14.43. Mn TnBut-2-PyPCl5×12.5H2O (MnC56H85N8O12.5Cl5). Found: C, 51.58; H, 6.33; N, 9.55; Cl, 15.53. Calculated: C, 51.64; H, 6.58; N, 8.60; Cl, 13.61. Mn TnHex-2-PyPCl5×10.5H2O (MnC64H97N8O12.5Cl5). Found: C, 55.64; H, 7.14; N, 8.23; Cl, 12.60. Calculated: C, 55.76; H, 7.09; N, 8.13; Cl, 12.86. MnIIITnOct-2-PyPCl5×10 H2O×2.5 NH4Cl (MnC64H122N10.5O10Cl7.5). Found: C, 53.56; H, 7.13; N, 9.12; Cl, 16.84. Calculated: C, 53.53; H, 7.60; N, 9.10; Cl, 16.46.
- Thin-layer chromatography. All ligands and their Mn(III) complexes were chromatographed on silica gel TLC plates using 1:1:8 KNO3-saturated H2O:H2O:acetonitrile. The atropoisomers could not be separated for the methyl19 and ethyl analogues,2-4 they begin to separate for the n-propyl and n-butyl species and were clearly resolved with the n-hexyl and n-octyl compounds.
- Uv/vis spectroscopy. The uv/vis spectra were taken on a Shimadzu UV-2501 PC spectrophotometer at 25° C. The proton dissociation constants (pKa2), were determined spectrophotometrically at 25° C., at an ionic strength of 0.1 M (NaOH/NaNO3), as previously described.4
- Electrochemistry. Measurements were performed on a CH Instruments Model 600 Voltammetric Analyzer.3,4 A three-electrode system in a small volume cell (0.5 mL to 3 mL), with a 3 mm-diameter glassy carbon button working electrode (Bioanalytical Systems), plus the Ag/AgCl reference and Pt auxillary electrodes was used. Solutions contained 0.05 M phosphate buffer, pH 7.8, 0.1 M NaCl, and 0.5 mM metalloporphyrin. The scan rates were 0.01-0.5 V/s, typically 0.1 V/s. The potentials were standardized against the potassium ferrocyanide/ferricyanide20 and/or against MnIIITE-2-PyP5+. All voltammograms were reversible.
- Electrospray mass spectrometry. ESMS measurements were performed on a Micromass Quattro LC triple quadrupole mass spectrometer equipped with a pneumatically assisted electrostatic ion source operating at atmospheric pressure. Typically, the 0.5 mM 50% aqueous acetonitrile solutions of chloride salts of metal-free porphyrins or their Mn(III) complexes were introduced by loop injection into a stream of 50% aqueous acetonitrile flowing at 8 μL/min. Mass spectra were acquired in continuum mode, scanning from 100-500 m/z in 5 s, with cone voltages of 20 V and 24 V. The mass scale was calibrated using polyethylene glycol.
- Catalysis of O2 •− dismutation. We have previously shown that the O2 •−/cytochrome c reduction assay gives the same catalytic rate constants as does pulse radiolysis for MnIIITE-2-PyP5+, {MnIIIBVDME}2, {MnIIIBV}2 and MnCl2.21 Therefore the convenient cytochrome c assay was used to characterize the series of Mn(III) N-alkylpyridylporphyrins. The xanthine/xanthine oxidase reaction was the source of O2 •− and ferricytochrome c was used as the indicating scavenger for O2 •−22 The reduction of cytochrome c was followed at 550 nm. Assays were conducted at (25±1)° C., in 0.05 M phosphate buffer, pH 7.8, 0.1 mM EDTA, in the presence and absence of 15 μg/mL of catalase. Rate constants for the reaction of metalloporphyrins with O2 •− were based upon competition with 10 μM cytochrome c, kcyt c=2.6×105 M−1 s−1 as described elsewhere.21 The O2 •− was produced at the rate of 1.2 μM per minute. Any possible interference through inhibition of the xanthine/xanthine oxidase reaction by the test compounds was examined by following the rate of urate accumulation at 295 nm in the absence of cytochrome c. No reoxidation of cytochrome c by the metalloporphyrins was observed.
- Thin Layer Chromatography. The increase in the length of the alkyl chains is accompanied by an increase in the lipophilicity of the compounds as indicated by the increase in the retention factor Rf (porphyrin path/solvent path) (Table 1,
FIG. 2 ). The apparent lag that was observed in the case of shorter chains with Mn(III) complexes (FIG. 2B ), is presumably due to their higher overall formal charge (+5 for the Mn(III) complexes, +4 for the ligand). As the chains lengthen, their contribution to the overall lipophilicity increases, and eventually the n-octyl porphyrin and its Mn(III) complex are more alike in Rf than are methyl analogues. - Uv/vis spectroscopy. Molar Absorptivities. The porphyrins obeyed the Beer-Lambert law from 10−7 M to 10−5 M, and the uv/vis data are given in Table 2. As the length of alkyl chains increased from methyl to n-butyl a red shift of the Soret absorption maxima was generally observed, as well as an increase in the molar absorptivities, and these effects plateau beyond butyl compound. Such trends may be understood in terms of the interplay of porphyrin nucleus distortion (red shifts) and the electron-withdrawing (blue shifts) effect of the N-alkylpyridyls groups.12,23
- Metalation behavior and proton dissociation constants. The rates of Mn2+ incorporation at pH ˜12.3 decreased with an increase in chain length. The same was found for the kinetics of Zn2+ and Cu2+ insertion into these compounds below
pH 7, where the kinetics were first order in metal and porphyrin concentration.24 Since the free-base porphyrin H2P4+ reactants were mixtures of the four atropoisomers, each isomer has a similar metalation rate constant. As noted before for both water soluble and insoluble porphyrins, compounds with substituents in the ortho positions tend to metalate more slowly than derivatives with the same groups in the meta or para positions.25-34 - The proton dissociation constants, Ka2 and Ka3 are defined as follows:
- The pKa2 values for the N-alkylpyridyl series are given in Table 1. As the alkyl chains lengthen the porphyrins become less hydrated and the separation of charges (eq [1]) becomes less favorable, i.e. pKa2 increases (
FIG. 3 , insert).FIG. 3A shows the linear relationship between pKa2 and Rf. - Equilibrium constants pKa3 for reaction [2] are 1.8 for the meta H2TM-3-PyP4+, 1.4 for the para H2TM-4-PyP4+, and −0.9 for ortho H2TM-2-PyP4+.4,25 While the meta and para N-methylpyridylporphyrins are mixtures of protonated H3P5+ and H4P6+ species in 1.0 M HCl, the ortho substituted H2TM-2-PyP4+ to H2TnOct-2-PyP4+ compounds remain as the unprotonated free base H2P4+ in 1.0 M HCl and in 1.0 M HNO3. With ortho, meta and para N-methylpyridylporphyrins the pKa2 increases as the pKa3 increases.
- The half-lives for the acid and anion-catalyzed removal of zinc from Zn N-methylated derivatives35 in 1.0 M HNO3 were 89 s for the meta, 165 s for the para, and 19 hours for the ortho ZnTM-2-PyP4+. No indication of zinc loss was found within a week for the ZnTnHex-2-PyP4+ compound.36 Similar behavior is found in 1.0 M HCl, with t1/2 ranging from 21 s for the meta methyl to 76 hours for ZnTnOct-2-PyP4+.24 In accord are the observations that when solid MnTnHex-2-Pyp5+ was dissolved in 12 M HCl, the spectra did not change within 3 months, while over 50% of the Mn from MnIIITM-2-PyP5+ species was lost within a month. In addition to porphyrin ring distortion,29-32 the steric hindrance and solvation effects imposed by the progressively longer alkyl chains may also contribute to the differences in metalation/demetalation behavior.
- Due to their high metal-centered redox potentials, the Mn(III) meso tetrakis ortho N-alkylpyridylporphyrins in vivo will be readily reduced with cell reductants such as ascorbic acid.2,3,12 The reduced Mn(II) porphyrins will also be transiently formed in the catalysis of O2 •− dismutation. Therefore, we also examined the behavior of the reduced and more biologically relevant MnIIIT(alkyl)-2-PyP4+ compounds. We compared the methyl, n-hexyl and n-octyl derivatives (6 μM) aerobically and anaerobically in the presence of a 70-fold excess of ascorbic acid (pH 7.8, 0.1 M tris buffer) and in the presence and absence of a 150-fold excess of EDTA. Under anaerobic conditions both Mn(II) porphyrins were stable to Mn loss and porphyrin decomposition inside 24 hours. Aerobically, ˜40% of Mn methyl but none of the Mn n-hexyl and n-octyl compounds underwent degradation within 125 min. The absorption spectral changes indicate that the degradation occurred through the Mn porphyrin catalyzed reduction of oxygen by ascorbate resulting in the formation of H2O2. The peroxide in turn causes porphyrin destruction. These observations are consistent with previous results which indicate that a more electron rich compound (MnIITM-2-PyP4+) reduces O2 faster than does a more electron deficient species (MnIITnOct-2-PyP4+).2,3 EDTA did not significantly influence porphyrin degradation or Mn loss.
- Electrochemistry. Cyclic voltammetry of the Mn(III) porphyrins shows a reversible voltammogram that we ascribe to the Mn(III)/Mn(II) redox couple. The metal-centered redox potentials, E1/2 are in Table 1 and the representative voltammograms of the MnIII/IITE-2-PyP5+/4+ and MnIII/IITnHex-2-PyP5+/4+ compounds are shown in the Supporting Material,
FIG. 6 . Both lipophilicity (FIG. 2B ) and E1/2 (FIG. 3B , insert) increase exponentially with the number of CH2 groups in the alkyl chains. Consequently, the increase in E1/2 is a linear function of Rf (FIG. 3B ). - Electrospray mass spectrometry. The ESMS proved to be a valuable tool for accessing the properties of the free base porphyrins and their Mn complexes whereby the impact of structure on solvation, ion-pairing, redox properties, protonation/deprotonation, dealkylation, and catalytic properties are clearly depicted.
- H2T(alkyl)-2-PyP4+. The ESMS of the metal-free porphyrins obtained at the low cone voltage of 20 V showed dominant molecular ions assigned to H2P4+/4 and/or its mono-deprotonated analogue, H2P4+−H+/3 (Table 3,
FIG. 7 ). Negligible double deprotonation (H2P4+−2H+/2) was noted. Only H2TM-2-PyP4+ gave rise to a high-intensity H2P4++H+/5 peak. - The ESMS shows a pronounced decrease in solvation by acetonitrile as the alkyl chains lengthen. Compared to the base peak, the relative intensities of the mono-solvated molecular ions range from 40% for methyl, 15% for ethyl, and <10% for the higher analogues. Only with the n-hexyl and n-octyl porphyrins are small peaks (<5%) from ions associated with chloride found.
- From methyl to n-butyl, the ratio of the molecular ion to mono-deprotonated ion peaks decreases, consistent with the trend in pKa2. Thus, the base peak for methyl is that of the molecular ion, while the base peak for the n-propyl and n-butyl porphyrins is the mono-deprotonated ion. This pKa2 trend is overcome by the higher lipophilicities of the n-hexyl and n-octyl compounds, where roughly equal-intensity molecular ion (100%) and mono-deprotonated ion (98%) peaks are observed. The loss of one alkyl group (H2P4+−a+/3) was noted for all derivatives (except for the methyl), and either no or negligible loss of a second alkyl group (H2P4+−2a+/2) was found.
- MnIIIT(alkyl)-2-PyP5+. The ESMS of the Mn(III) complexes was done at a lower cone voltage (20 V) than in our previous study (30-58 V).37 Therefore, less fragmentation occurs and more solvent-associated and ion-paired species could be observed (Table 4,
FIG. 8 ). Solvation and ion pairing are more pronounced when compared with the metal-free ligands. The more lipophilic Mn(III) porphyrins are more easily desolvated in the electrospray ionization source. In accordance with our previous observations, the ESMS also clearly reflects the redox properties of these compounds.37,38 The higher the E1/2 the more reduced porphyrins are noted. Species solvated with acetonitrile or associated with chloride were observed with both Mn(III) and Mn(II) compounds. Two chlorides were associated only with Mn(III) porphyrins. - In the ESMS of the n-hexyl and n-octyl porphyrins we observed strong signals at m/
z - The ESMS behavior of Mn porphyrins changes sharply once the alkyl chains lengthen beyond butyl, as observed with corresponding metal-free analogues. No loss of methyl groups was detected.37 As the chains lengthen up to butyl the loss of an alkyl group from Mn(III) and Mn(II) porphyrins becomes more pronounced and then the tendency decreases with n-hexyl and n-octyl. The same trend, but of lower intensity was noted for the loss of two alkyl groups. The ratio of mono-chlorinated Mn(III) to mono-chlorinated Mn(II) species decreases from methyl to n-butyl and then increases up to n-octyl. Thus the base peak of the methyl and ethyl porphyrins relates to MnIIIP5++Cl−/4, while for the n-propyl and n-butyl derivatives it relates to MnIIIP4++Cl−/3. Yet, with the n-hexyl, the MnIIIP5++Cl−/4 and MnIIP4++Cl−/3 peaks are both of 100% intensity, and the di-chlorinated species (MnIIIP5++2Cl−/3) is of 86% intensity. With the n-octyl analogue, the mono- and di-chlorinated species give rise to 100% MnIIIP5+Cl−/4 and 89% MnIIIP5++2Cl−/3peaks, and the third most intense (59%) signal relates to MnIIP4++Cl−/3. The lack of significant association of metal-free porphyrins with chloride observed here and elsewhere,37 strongly supports the idea that chloride is bound to the metal. Furthermore, at the same cone voltage, the base peak of ortho MnTM-2-PyP5+ is the mono-chlorinated species, which was only 35% for para isomer. This suggests that the longer the chains, the more defined the cavity, which can hold up to two chloride ions, and the more stable is the Mn(III) state. While a species bearing two chlorides is hardly noted in MnIIITM-2-PyP5+, it is the second major peak in the ESMS of MnIIITnOct-2-PyP5+.
- Catalysis of O2 •− dismutation. None of the parent metal-free porphyrins exhibit any O2 •− dismuting activity. All of the manganese compounds are potent catalysts of O2 •− dismutation with log kcat between 7.79 and 7.25. As shown in Table 1, log kcat decreases from methyl to n-butyl and then increases, making n-octyl and methyl of comparable antioxidant potency.
- When designing metalloporphyrin SOD mimics we are aiming at approximating the redox properties of the enzyme active site. Superoxide dismutases catalyse the dismutation (disproportionation) of O2 •− to H2O2 and O2 at ˜+300 V vs NHE (pH 7.0).39,40 This potential is roughly midway (+360 mV vs NHE) between the potential for the reduction (+890 V vs NHE)41 and the oxidation of O2 •− (˜60 V vs NHE)41 thus providing an equal driving force for both half-reactions in the catalytic cycle. The O2 •− dismutation by Cu,Zn-SOD occurs with catalytic rate constant, kcat=kred=kox≅2×109 M−1 s−1 (log kcat≅9.3).42-44
- We previously demonstrated a structure-activity relationship between log kcat and the metal-centered E1/2 of the Mn(III)/Mn(II) couple for a variety of water-soluble meso substituted porphyrins (FIG. 4A).2-4 Electron-withdrawing substituents on the porphyrin ring shift E1/2 towards more positive values resulting in higher values for kcat. 2-4 Each 120 mV increase in E1/2 gave a 10-fold increase in kcat,4 consistent with the Marcus equation45 for outer-sphere electron transfer reactions (
FIG. 4A ). The Marcus equation is valid as long as one of the two steps in the catalytic dismutation cycle is - rate-limiting.
- On the basis of such structure-activity relationships, the ortho isomers of Mn(III) meso tetrakis N-methyl- and N-ethylpyridylporphyrins were tested and proved to be potent catalysts of O2 •− dismutation. Their log kcat values are 7.79 and 7.76 and they operate at potentials (+220 and +228 V) similar to the potential of the enzyme itself. These two metalloporphyrins also exhibit protection in in vivo models of oxidative stress injuries.14-17 We have now extended our work to a series of MnIIIT(alkyl)-2-PyP5+ compounds where alkyl is methyl, ethyl, n-propyl, n-butyl, n-hexyl, and n-octyl (
FIG. 1 ). The significant differences in lipophilicity along the series (FIG. 2A ), with retention of catalytic potency (Table 1), might lead to favorably selective subcellular distributions of these new MnIIIT(alkyl)-2-PyP5+ compounds and hence broader their utility. - E1/2 vs pKa2. We did not expect a profound change in E1/2 along the series based on the fact that the increase in alkyl chain length from methyl to n-hexyl is without effect on the basicity of alkylamines.46 However, we found that the metal-centered redox potentials varied from +220 mV for methyl to +367 mV (vs NHE) for the n-octyl compound. Such an increase in E1/2 may originate from progressively unshielded positive charges at pyridyl nitrogens which would then exert stronger electron-withdrawing effect on the coordinated Mn as the compounds increase in lipophilicity. This reasoning is supported by the ESMS data (Table 4,
FIG. 8 ) which show that the susceptibility to desolvation is accompanied by a greater preponderance of reduced Mn(II) porphyrin ions as the alkyl chains of the Mn complexes lengthen. We have previously reported4 that mainly electronic effects determine the relation between the pKa of the metal-free porphyrin and the E1/2 of the corresponding metal complex such that the decrease in pKa3 is accompanied by a linear increase in E1/2 (FIG. 5 , insert). However as the compounds become increasingly more lipophilic, the lack of solvation disfavors separation of charges (higher pKa2 values), while the electron-withdrawing effects of the positively charged pyridyl nitrogen are enhanced. Thus the electronic pKa2 effects are overcome by solvation/steric effects resulting in an inverted trend, i.e. the E1/2 now increases in a linear fashion with an increase in pKa2 (FIG. 5 ). - Log kcat vs E1/2. Based on a previously established structure-activity relationship for water-soluble Mn(III) porphyrins,4 we expected the 147 mV increase in E1/2 to be accompanied by a ˜12-fold increase in kcat (FIG. 4A).4 We actually found that kcat decreased from methyl to n-butyl, and then increased by the same factor of ˜3 to n-octyl (Table 1,
FIG. 4B ). One explanation is that the Mn porphyrins are solvated to different extents, as indicated by the ESMS data, and this in turn affects the magnitude of kcat. The trend in kcat may also be influenced by the electrostatic/steric effects originating from the shielding of the single positive charge on the Mn(III) center. Thus the difference in the magnitude of lipophilicity between the metal-free ligands (formally +4) and the Mn(III) complexes (formally +5) becomes less noticeable as the alkyl chains get longer (Table 1). These H2P4+ compounds of formal +4 charge behave in solution kinetically as +1.6 to +1.8 electrolytes.24 From methyl to n-butyl, log kcat decreases almost linearly (FIG. 4B , insert). Due to the exponential increase in E1/2 along the series of Mn porphyrins (FIG. 3B , insert), the unfavorable electrostatic/steric effects are in part opposed and finally overcome by the progressively more favorable redox potentials that originate from increased desolvation (lipophilicity). Consequently, the very lipophilic n-octyl compound is essentially as potent an SOD mimic as the less lipophilic methyl and ethyl derivatives. - Regan et al47 were able to uncouple the steric and solvation effects in reactions of chloride ions with methyl- and tert-butyl-substituted chloroacetonitrile, and showed that both were of comparable magnitudes. Similarly, the reactivity of N-alkylpyridylporphyrins are the result of the interplay of electronic, steric and solvation effects, the latter dominating with the more lipophilic members of the series.
- Recent findings indicate that biologically relevant reactions, other than O2 •− dismutation, can occur at the metal center in Mn porphyrins.2,3,5,7,8,48-52 The same has been reported for the enzyme active site,20,53-57 thus raising the complexity of the free radical chemistry and biology of the enzymes and their mimics. Reactive oxygen and nitrogen species are involved in direct damage of key biological targets such as nucleic acids, proteins and fatty acids, and there is an increasing amount of evidence that such species are also involved in the modulation of signaling processes.14,58,59 Thus, it is important to understand the mechanisms of action of Mn porphyrins and related compounds. Based on the electrostatic, steric, solvation, and lipophilic effects observed in this study, we expect the members of N-alkylpyridyl series to differ one from another in in vivo models of oxidative stress injuries with respect to their specificity towards reactive oxygen and nitrogen species as well as with regard to their pharmacokinetics. Such work is in progress.
- SOD, superoxide dismutase; AN, acetonitrile; DMF, N,N-dimethylformamide; NHE, normal hydrogen electrode; TLC, thin-layer chromatography; H2P4+, any meso tetrakis N-alkylpyridylporphyrin ligand; MnIII/IIP4+/5+, any Mn(III/II) meso tetrakis N-alkylpyridylporphyrin; meso refers to the substituents at the 5,10,15, and 20 (meso carbon) position of the porphyrin core. MnIIIT(alkyl)-2(3,4)-PyP5+, manganese(III) meso tetrakis(N-methyl, N-ethyl, N-n-propyl, N-n-butyl, N-n-hexyl, N-n-octyl)pyridinium-2(3,4)-yl)porphyrin; alkyl is M, methyl; E, ethyl; nPr, n-propyl; nBu, n-butyl; nHex, n-hexyl; nOct, n-octyl on the pyridyl ring; 2 is the ortho, 3, the meta and 4 the para isomer; MnIIITM-2-PyP5+ is AEOL-10112, and MnIIITE-2-PyP5+ is AEOL-10113; MnIIIPTr(M-2-PyP4+, manganese(III) 5-phenyl-10,15,20-tris (N-methylpyridinum-2-yl)porphyrin; MnIIIBM-2-PyP3+, manganese(III) meso bis(2-pyridyl)-bis(N-methylpyridinium-2-yl)porphyrin; MnIIITrM-2-PyP4+, 5-(2-pyridyl)-10,15,20-tris(N-methylpyridinium-2-yl)porphyrin; MnIIIT(TMA)P5+, manganese(III) meso tetrakis(N,N, N-trimethylanilinium-4-yl)porphyrin; MnIIIT(TFTMA)P5+, manganese(III) meso tetrakis(2,3,5,6-tetrafluoro-N,N,N-trimethylanilinium-4-yl)poprhyrin; MnIIITCPP3−, manganese meso tetrakis(4-carboxylatophenyl)porphyrin; MnTSPP3−, manganese(III) meso tetrakis(4-sulfonatophenyl)porphyrin; MnIIIT(2,6-Cl2-3-SO3—P)P3−, manganese(III) meso tetrakis(2-6-dichloro-3-sulfonatophenyl)porphyrin; MnIIIT(2,6-F2-3-SO3—P)P3−, manganese(III) meso tetrakis(2,6-difluoro-3-sulfonatophenyl)porphyrin; MnIIIT(2,4,6-Me3-3,5-(SO3)2—P)P7−, manganese(III) 5,10,15,20-tetrakis(2,4,6,-trimethyl-3,5-disulfonatophenyl)porphyrin; MnIIIhematoP−, manganese(III) hematoporphyrin IX.
-
- 1. R. F. Pasternack, A. Banth, J. M. Pasternack and C. S. Johnson, J. Inorg. Biochem. 1981, 15, 261 (b) R. F. Pasternack and B. J. Halliwell, J. Am. Chem. Soc. 1979, 101, 1026.
- 2.1. Batinić-Haberle, Methods Enzymol. 2002, 349, 223.
- 3.1. Spasojević and I. Batinić-Haberle, Inorg. Chim. Acta, 2001, 317, 230.
- 4. I Batinić-Haberle, I. Spasojević, P. Hambright, L. Benov, A. L. Crumbliss and I. Fridovich, Inorg. Chem. 1999, 38, 4011.
- 5. G. Ferrer-Sueta, I. Batinić-Haberle, I. Spasojević, I. Fridovich and R. Radi, Chem. Res. Toxicol. 1999, 12, 42.
- 6. R. Kachadourian, I. Batinić-Haberle and I. Fridovich, Inorg. Chem. 1999, 38, 391.
- 7. J. Lee, J. A. Hunt and J. T. Groves, J. Am. Chem. Soc. 1998, 120, 6053.
- 8. J. P. Crow, Arch. Biochem. Biophys. 1999, 371, 41.
- 9. M. Patel and B. J. Day, Trends Pharmacol. 1999, 20, 359.
- 10. (a) K. Aston, N. Rath, A. Naik, U. Slomczynska, O. F. Schall and D. P. Riley, Inorg. Chem. 2001, 40, 1779. (b) S. Cuzzocrea, E. Mazzon, L. Dugo, A. P. Caputi, K. Aston, D. P. Riley and D. Salvemini, Br. J. Pharmacol. 2001, 132, 19.
- 11. (a) S. Melov, J. Ravenscroft, S. Malik, M. S. Gill, D. W. Walker, P. E. Clayton, D. C. Wallace, B. Malfroy, S. R. Doctrow and G. J. Lithgow, Science, 2000, 289, 1567. (b) K. Baker, C. Bucay Marcus, K. Huffman, H. Kruk, B. Malfroy and S. R. Doctrow, J. Pharmacol. Exp. Ther., 1998, 284, 215.
- 12. I. Batinić-Haberle, L. Benov, I. Spasojević and I. Fridovich, J. Biol. Chem., 1998, 273, 24521.
- 13.1. Spasojević, R. Menzeleev, P. S. White and I. Fridovich, Inorg. Chem., 2002, submitted.
- 14. G. B. Mackensen, M. Patel, H. Sheng, C. C. Calvi, I. Batinić-Haberle, B. J. Day, L. P. Liang, I. Fridovich, J. D. Crapo, R. D. Pearlstein and D. S. Warner, J. Neurosci., 2001, 21, 4582.
- 15. J. D. Piganelli, S. C. Flores, C. Cruz, J. Koepp, I. Batinić-Haberle J. Crapo, B. J. Day, R. Kachadourian, R. Young, B. Bradley and K. Haskins, Diabetes, 2002, 51, 347.
- 16. M. Aslan, T. M. Ryan, B. Adler, T. M. Townes, D. A. Parks, J. A. Thompson, A. Tousson, M. T. Gladwin, M. M. Tarpey, M., R. P. Patel, I. Batinić-Haberle, C. R. White and B. A. Freeman, Proc. Natl. Acad. Sci. USA, 2001, 98, 15215.
- 17. (a) I. Batinić-Haberle, I. Spasojević, I. Fridovich, M. S. Anscher and {hacek over (Z)}. Vujaŝkovic, Proc of the 43rd Annual Meeting of American Society for Therapeutics in Radiation Onciology, San Francisco 2001, 235-236. (b) Z. Vujaŝković, I. Batinić-Haberle, I. Spasojević, T. V. Samulski, M. W. Dewhirst and M. S. Anscher, Annual Meeting of Radiation Research Society, San Juan, Puerto Rico 2001. (c) {hacek over (Z)}. Vujaŝković, I. Batinić-Haberle, I. Spasojević, Irwin Fridovich, M. S. Anscher and M. W. Dewhirst, Free Rad. Biol. Med. 2001, S128.
- 18. W. R. Waud, F. O. Brady, R. D. Wiley and K. V. Rajagopalan, Arch. Biochem. Biophys. 1975, 19, 695.
- 19. T. Kaufmann, T., B. Shamsai, R. S. Lu, R. Bau and G. M. Miskelly, Inorg. Chem. 1995, 34, 5073.
- 20.1. M. Kolthof and W. J. Tomsicek, W. J., J. Phys. Chem. 1935, 39, 945.
- 21.1. Batinić-Haberle, I. Spasojević, R. D. Stevens, P. Hambright, A. N. Thorpe, J. Grodkowski, P. Neta and I. Fridovich, Inorg. Chem. 2001, 40, 726.
- 22. J. M. McCord and I. Fridovich, J. Biol. Chem. 1969, 244, 6049.
- 23.1. Batinić-Haberle, S. I. Liochev, I. Spasojević and I. Fridovich, Arch. Biochem. Biophys. 1997, 343, 225.
- 24. P. Hambright, I. Spasojević, I. Fridovich and I. Batinić-Haberle, in preparation.
- 25. P. Hambright, Water-Soluble Metalloporphyrins in The Porphyrin Handbook, K. M. Kadish, K. M. Smith, R. Guillard, Eds. Academic Press, N.Y. 2000, Chapter 18.
- 26. T. P. G. Sutter and P. Hambright, J. Coord. Chem. 1993, 30, 317.
- 27. L. R. Robinson and P. Hambright, Inorg. Chem., 1992, 31, 652.
- 28. J. B. Reid and P. Hambright, Inorg. Chem. 1977, 16, 968.
- 29. M. Inamo, N. Kamiya, Y. Inada, M. Nomura and S. Funahashi, Inorg Chem., 2001, 40, 5636.
- 30. P. B. Chock and P. Hambright, J. Am. Chem. Soc. 1974, 96, 3123.
- 31. S. Funahashi, Y. Inada and M. Inamo, Anal. Sci. 2001, 17, 917.
- 32. T. P. G. Sutter, R. Rahimi, P. Hambright, J. Bommer, M. Kumar and P. Neta, J. Chem. Soc. Faraday Trans. 1993, 84, 495.
- 33. B. Cheng, O. Q. Munro, H. M. Marques and W. R. Scheidt, J. Am. Chem. Soc. 1997, 119, 10732.
- 34. R. F. Pasternack, N. Sutin and D. H. Turner, J. Am. Chem. Soc. 1976, 98, 1908.
- 35. P. Hambright, T. Gore and M. Burton, Inorg. Chem. 1976, 15, 2314.
- 36. J, Davilla, A. Harriman, M.-G. Richoux and L. R. Milgrom, J. Chem. Soc. Chem. Commun. 1987, 525.
- 37.1. Batinić-Haberle, R. D. Stevens and L Fridovich, J. Porphyrins Phthalocyanines, 2000, 4, 217.
- 38. R. Kachadourian, N. Srinivasan, C. A. Haney and R. D. Stevens, J Porphyrins Phthalocyanines, 2001, 5, 507.
- 39. Vance, C. K. and Miller, A.-F., Biochemistry, 2001, 40, 13079.
- 40. (a) G. D. Lawrence and D. T. Sawyer, Biochemistry, 1979, 18, 3045. (b) W. C. Jr. Barrette, D. T. Sawyer, J. A. Free and K. Asada, Biochemistry 1983, 22, 624.
- 41. Wood, P. M., Biochem. J, 1988, 253, 287.
- 42. Vance, C. K. and Miller, A.-F., J. Am. Chem. Soc., 1998, 120, 461.
- 43. R. M. Ellerby, D. E. Cabelli, J. A. Graden and J. S. Valentine, J. Am. Chem. Soc., 1996, 118, 6556.
- 44. D. Klug-Roth, I. Fridovich and J. Rabani, J. Am. Chem. Soc., 1973, 95, 2786.
- 45. R. A. Marcus, Annu. Rev. Phys. Chem., 1964, 15, 155.
- 46. CRC Handbook of Chemistry and Physics, D. R. Lide, Editor-in-Chief, 74th Edition, 1993-1994, CRC Press, Boca Raton.
- 47.1. Spasojević, I. Batinić-Haberle and I. Fridovich, Nitric Oxide: Biology and
Chemistry 2000, 4, 526. - 48. (a) C. K. Regan, S. L. Craig and J. I. Brauman, Science, 2002, 295, 2245.
- 49. R. Shimanovich and J. T. Groves, Arch. Biochem. Biophys., 2001, 387, 307.
- 50. N. Jin, J. L. Bourassa, S. C. Tizio and J. T. Groves, Angew. Chem. Int. Ed., 2000, 39, 3849.
- 51. H. Zhang, J. Joseph, M. Gurney, D. Becker and B. Kalyanaraman, J. Biol. Chem., 2002, 277, 1013.
- 52. N. Motohashi and Y. Saito, Chem. Pharm. Bull., 1995, 43, 505.
- 53. C. Quijano, D. Hernandez-Saavedra, L. Castro, J. M. McCord, B. A. Freeman and R. Radi, J. Biol. Chem., 2001, 276, 11631.
- 54. (a) S. L. Jewet, A. M. Rocklin, M. Ghanevati, J. M. Abel and J. A. Marach, Free Rad Biol. Med., 1999, 26, 905. (b) S. P. A. Goss, R. J. Singh and B. Kalyanaraman, J. Biol. Chem., 1999, 274, 28233. (c) S. I Liochev and I. Fridovich, Free Rad Biol. Med., 199, 27, 1444.
- 55. (a) A. G. Estevez, J. P. Crow, J. B. Sampson, L. Reither, J. Zhuang, G. J. Richardson, M. M. Tarpey, L. Barbeito and J. S. Beckman, Science, 1999, 286, 2498. (b) S. I. Liochev and I. Fridovich, J. Biol. Chem., 2001, 276, 35253.
- 56. S. I. Liochev and I. Fridovich J. Biol. Chem., 2000, 275, 38482.
- 57. E. D. Coulter, J. P. Emerson, D. M. Jr., Kurtz and D. E. Cabelli, J. Am. Chem. Soc., 2000, 122, 11555.
- 58. B. M. Matata and M. Galinanes, J. Biol. Chem., 2002, 277, 2330.
- 59. (a) {hacek over (Z)}. Vujaŝković, I. BatinićHaberle, M. S. Anscher, Z. N. Rabbani, T. V. Samulski, K. Amin, M. W. Dewhirst and Z. Haroon, Proc. of the 43rd Annual Meeting of American Society for Therapeutics in Radiation Onciology, San Francisco 2001, 88-89. (b) {hacek over (Z)}. Vujaŝković, I. Batinić-Haberle, Z. N. Rabbani, Q.-F. Feng, S. K. Kang, I. Spasojević, T. V. Samulsli, I. Fridovich, M. W. Dewhirst, M. S. Anscher, Free Rad Biol. Med. In press.
-
TABLE 1 Metal-Centered Redox Potentials E1/2, log kcat for O2 .− Dismutation, and Chromatographic Rf values. E1/2 c Porphyrin Rf a pKa2 b mV vs NHE log kcat d MnIIITM-2-PyP5+ 0.09 (0.13) 10.9 +220 7.79 MnIIITE-2-PyP5+ 0.13 (0.21) 10.9 +228 7.76 MnIIITnPr-2-PyP5+ 0.20 (0.31) 11.4 +238 7.38 MnIIITnBut-2-PyP5+ 0.33 (0.46) 11.7 +254 7.25 MnIIITnHex-2-PyP5+ 0.57 (0.63) 12.2 +314 7.48 MnIIITnOct-2-PyP5+ 0.80 (0.86) 13.2 +367 7.71 aRf (compound path/solvent path) on silica gel TLC plates in 1:1:8 KNO3-saturated H2O:H2O:acetonitrile. Rf for the metal-free porphyrins are in parentheses. bpKa2 determined at 25° C. ionic strength 0.10 (NaNO3/NaOH). cE1/2 determined in 0.05 M phosphate buffer (pH 7.8, 0.1 M NaCl). dkcat determined using the cytochrome c assay, in 0.05 M phosphate buffer, pH 7.8, at (25 ± 1) ° C. -
TABLE 2 Molar Absorptivities of Tetrads (N-alkylpyridinium-2-yl)porphyrin chlorides and their Mn(III) Complexes. Porphyrin λnm (log ε)a H2TM-2-PyP4+ 413.2(5.32); 510.4(4.13); 544.4(3.49); 581.4(3.72); 634.6(3.13) H2TE-2-PyP4+ 414(5.33); 511(4.20); 545(3.58); 582(3.80); 635(3.38); H2TnPr-2-PyP4+ 415(5.38); 511.5(4.24); 545(3.62); 583(3.84); 635(3.37) H2TnBut-2-PyP4+ 415(5.37); 511(4.24); 544(3.60); 583(3.84); 636(3.39) H2TnHex-2-PyP4+ 415.5(5.34); 510.5(4.24); 543(3.62); 584.5(3.84); 638(3.43) H2TnOct-2-PyP4+ 416.5(5.31); 510(4.25); 542(3.59); 585(3.82); 639.5(3.43) MnIIITM-2-PyP5+ 363.5(4.64); 411(4.27); 453.4(5.11); 499(3.66); 556(4.03); 782(3.15) MnIIITE-2-PyP5+ 363.5(4.68); 409(4.32); 454(5.14); 499(3.75); 558(4.08); 782(3.26) MnIIITnPr-2-Pyp5+ 363(4.70); 411(4.37); 454(5.21); 498(3.81); 559(4.12); 782(3.35) MnIIITnBut-2-PyP5+ 364(4.70); 410(4.35); 454(5.23); 498(3.83); 559(4.14); 781(3.33) MnIIITnHex-2-PyP5+ 364.5(4.70); 415(4.57); 454.5(5.21); 507(3.85); 560(4.12); 780(3.30) MnIIITnOct-2-PyP5+ 364(4.72); 414(4.44); 454.5(5.24); 500.5(3.84); 559.5(4.14); 781(3.25) aThe molar absorptivities were determined in water at room temperature. -
TABLE 3 EIectrospray Mass Spectrometry Results for H2T(alkyl)-2-PyP4+ Compounds.a m/z Speciesb M E nPr nBu nHex nOct H2P4+/4 169 184 198 212 239 268 H2P4++AN/4 180 194 208 222 250 H2P4++2AN/4 190 H2P4+−H+/3 226 245 263 282 319 357 H2P4+−H++AN/3 240 258 278 H2P4+−H++H2O/3 288 H2P4+−H++Cl−/2 496 H2P4+−a+/3 235 249 263 291 319 H2P4+−a+−H+/2 352 374 394 436 H2P4+−a++H2O/3 255 H2P4+−2a+/2 352 366 H2P4++H+/5 136 H2P4++H++AN/5 143 H2P4++H++2AN/5 152 H2P4++H++2Cl−/3 343 381 H2P4++2H++2Cl−/4 286 H2P4+−2H+/2 339 367 395 423 479 a~0.5 mM solutions of H2P4+ in 1:1 acetonitrile:water, 20 V cone voltage. bAN denotes acetonitrile and a is an alkyl group. -
TABLE 4 Electrospray Mass Spectrometry for MnIIIT(alkyl)-2-PyP5+ Porphyrins.a m/z Speciesb M E nPr nBu nHex nOct MnIIIP5++5 146 157 MnIIIP5++AN/4 155 166 177 188 MnIIIP5++2AN/5 163 174 185 196 MnIIIP5++3AN/5 171 182 193 205 MnIIIP5++4AN/5 179 190 213 MnIIIP5++5AN/5 187 198 MnIIIP5++6AN/5 195 MnIIIP5++H2O/5 150 MnIIIP5++Cl−/4 192 206 234 262 290 MnIIIP5++2Cl−/3 267 286 305 323 361 398 MnIIIP5++2Cl−+AN/4 202 216 230 244 272 MnIIIP5+−a/4 200 MnIIIP5+−a+AN/4 200 221 242 MnIIIP5+−a+2Cl−/3 264 279 293 321 349 MnIIIP5+−2a/3 243 252 262 299 MnIIIP5+−2a+AN/3 275 294 MnIIP4+/4 183 197 211 281 MnIIP4++AN/4 193 207 221 235 263 MnIIP4++2AN/4 204 MnIIP4+/Cl−/3 255 274 293 312 349 387 MnIIP4+−a/3 253 266 281 309 337 MnIIIP5+−Mn3++H+/3 281 319 357 MnIIP−3+/3 or MnIP3+/3 294 337 375 a~0.5 mM solutions of MnIIIP5+ in 1:1 acetonitrile:water, 20 V cone voltage. bAN denotes acetonitrile and a is an alkyl group.
Claims (6)
1.-5. (canceled)
6. A method of protecting cells from oxidant-induced toxicity comprising contacting said cells with a protective amount of a compound under conditions such that the protection is effected, said compound having the formula
wherein
each R is, independently, an alkyl group of greater than 8 carbons,
each A is, independently, hydrogen or a halogen,
M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc, and
Z− is a counterion.
7. The method according to claim 6 wherein said cells are mammalian cells.
8. A method of treating a pathological condition of a patient resulting from oxidant-induced toxicity comprising administering to said patient an effective amount of a compound under conditions such that the treatment is effected, said compound having the formula
wherein
each R is, independently, an alkyl group of greater than 8 carbons,
each A is, independently, hydrogen or a halogen,
M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc, and
Z− is a counterion.
9. A method of treating a pathological condition of a patient resulting from degradation of NO•, comprising administering to said patient an effective amount of a compound under conditions such that the treatment is effected, said compound having the formula
wherein
each R is, independently, an alkyl group of greater than 8 carbons,
each A is, independently, hydrogen or a halogen,
M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc, and
Z− is a counterion.
10. A method of treating a patient for inflammatory lung disease comprising administering to said patient an effective amount of a compound under conditions such that the treatment is effected, said compound having the formula
wherein
each R is, independently, an alkyl group of greater than 8 carbons,
each A is, independently, hydrogen or a halogen,
M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc, and
Z− is a counterion.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/025,612 US20080207582A1 (en) | 2002-06-07 | 2008-02-04 | Substituted Porphyrins |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38645402P | 2002-06-07 | 2002-06-07 | |
US10/456,956 US7485721B2 (en) | 2002-06-07 | 2003-06-09 | Substituted porphyrins |
US12/025,612 US20080207582A1 (en) | 2002-06-07 | 2008-02-04 | Substituted Porphyrins |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/456,956 Division US7485721B2 (en) | 2002-06-07 | 2003-06-09 | Substituted porphyrins |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080207582A1 true US20080207582A1 (en) | 2008-08-28 |
Family
ID=29736167
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/456,956 Expired - Fee Related US7485721B2 (en) | 2002-06-07 | 2003-06-09 | Substituted porphyrins |
US12/025,612 Abandoned US20080207582A1 (en) | 2002-06-07 | 2008-02-04 | Substituted Porphyrins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/456,956 Expired - Fee Related US7485721B2 (en) | 2002-06-07 | 2003-06-09 | Substituted porphyrins |
Country Status (6)
Country | Link |
---|---|
US (2) | US7485721B2 (en) |
EP (1) | EP1513537A4 (en) |
JP (1) | JP2006501163A (en) |
AU (1) | AU2003237500A1 (en) |
CA (1) | CA2488500A1 (en) |
WO (1) | WO2003103680A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
AU2005231336A1 (en) * | 2004-03-29 | 2005-10-20 | Inotek Pharmaceuticals Corporation | Pyridyl-Substituted Porphyrin Compounds and methods of use thereof |
GB2415372A (en) | 2004-06-23 | 2005-12-28 | Destiny Pharma Ltd | Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent |
US20060069782A1 (en) * | 2004-09-16 | 2006-03-30 | Michael Manning | Method and apparatus for location-based white lists in a telecommunications network |
GB0424294D0 (en) * | 2004-11-03 | 2004-12-01 | Elam T Ltd | Buffer layer |
US7642250B2 (en) * | 2005-09-28 | 2010-01-05 | Inotek Pharmaceuticals Corporation | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof |
JP4891367B2 (en) | 2009-05-21 | 2012-03-07 | トヨタ自動車株式会社 | Solvent composition |
AU2010254117A1 (en) * | 2009-05-26 | 2012-01-19 | Duke University | Method of providing neuroprotection using substituted porphyrins |
JP2015500244A (en) | 2011-12-02 | 2015-01-05 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | Metalloporphyrin neurological treatment |
US9034596B1 (en) | 2014-04-17 | 2015-05-19 | Kuwait University | Method for fluorescent staining of cellular and intracellular membranes |
EP3558902A4 (en) * | 2016-12-20 | 2020-06-24 | Duke University | Methods of making substituted porphyrin pharmaceutical compounds and compositions |
WO2018237249A1 (en) * | 2017-06-22 | 2018-12-27 | Biomimetix Jv, Llc | Methods, compositions, and kits for treating inflammatory skin conditions |
Citations (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2951799A (en) * | 1957-11-13 | 1960-09-06 | Monsanto Chemicals | Photoxidation processes using heterocyclic photosensitizers |
US4614723A (en) * | 1983-06-03 | 1986-09-30 | Hoffmann-La Roche Inc. | Porphyrin derivatives as fluorescent markers for immunoassays |
US4657902A (en) * | 1985-03-25 | 1987-04-14 | The Rockefeller University | Therapeutic use of tin mesoporphyrin |
US4746735A (en) * | 1986-11-21 | 1988-05-24 | The Dow Chemical Company | Regiospecific aryl nitration of meso-substituted tetraarylporphyrins |
US4758422A (en) * | 1985-01-04 | 1988-07-19 | Salutar Inc. | Ferrioxamine paramagnetic contrast agents for MR imaging |
US4829984A (en) * | 1983-12-15 | 1989-05-16 | Gordon Robert T | Method for the improvement of transplantation techniques and for the preservation of tissue |
US4837221A (en) * | 1984-11-26 | 1989-06-06 | Efamol Ltd. | Methods of treating tumors susceptible to necrosis |
US4851403A (en) * | 1987-04-21 | 1989-07-25 | Johnson Matthey, Inc. | Radiation sensitizers |
US4866054A (en) * | 1986-05-13 | 1989-09-12 | Chai-Tech Corporation | Antioxidant metallo-organic treatment of inflammation |
US4885114A (en) * | 1987-04-22 | 1989-12-05 | Barnes Engineering Co. | Metallized tetra((meso)-5-methyl-2-thiophene)porphines, platinum (5-bromo octaethylporphine) and optical filters containing same |
US4892941A (en) * | 1987-04-17 | 1990-01-09 | Dolphin David H | Porphyrins |
US4895719A (en) * | 1985-05-22 | 1990-01-23 | Liposome Technology, Inc. | Method and apparatus for administering dehydrated liposomes by inhalation |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US5010073A (en) * | 1989-10-05 | 1991-04-23 | The Rockefeller University | Use of liposomes as carriers for metalloporphyrins |
US5051337A (en) * | 1987-06-10 | 1991-09-24 | Director-General Of Agency Of Industrial Science And Technology | Optical recording material |
US5087438A (en) * | 1984-07-03 | 1992-02-11 | Gordon Robert T | Method for affecting intracellular and extracellular electric and magnetic dipoles |
US5109016A (en) * | 1988-05-23 | 1992-04-28 | Georgia State University Foundation, Inc. | Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions |
US5130245A (en) * | 1985-09-03 | 1992-07-14 | Stefan Marklund | Superoxide dismutase |
US5162519A (en) * | 1988-03-11 | 1992-11-10 | Efamol Holdings Plc | Porphyrins and cancer treatment |
US5169630A (en) * | 1989-10-19 | 1992-12-08 | Pola Chemical Industries, Ltd. | External skin preparation |
US5171680A (en) * | 1988-06-14 | 1992-12-15 | Chiron Corporation | Superoxide dismutase analogs having novel binding properties |
US5192757A (en) * | 1990-12-20 | 1993-03-09 | Glaxo Inc. | Cobalt porphyrins |
US5192788A (en) * | 1988-05-23 | 1993-03-09 | Georgia State University Foundation, Inc. | Porphyrin antiviral compositions |
US5202317A (en) * | 1990-09-13 | 1993-04-13 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
US5217966A (en) * | 1990-09-13 | 1993-06-08 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
US5223538A (en) * | 1987-03-31 | 1993-06-29 | Duke University | Superoxide dismutase mimic |
US5227405A (en) * | 1987-03-31 | 1993-07-13 | Duke University | Superoxide dismutase mimic |
US5236914A (en) * | 1988-06-02 | 1993-08-17 | Centre National De La Recherche Scientifique (Cnrs) | Derivatives of metalloporphyrins and application thereof for therapeutic purposes and in preparing hybrid molecules |
US5236915A (en) * | 1990-05-31 | 1993-08-17 | Health Research, Inc. | Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing agents |
US5248603A (en) * | 1985-09-03 | 1993-09-28 | Symbicom Aktiebolag | Superoxide dismutase |
US5262532A (en) * | 1991-07-22 | 1993-11-16 | E.R. Squibb & Sons, Inc. | Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging |
US5277908A (en) * | 1990-11-14 | 1994-01-11 | The Uab Research Foundation | Modified superoxide dismutase |
US5284647A (en) * | 1988-03-18 | 1994-02-08 | Schering Aktiengesellschaft | Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them |
US5366729A (en) * | 1989-09-15 | 1994-11-22 | Symbicom Aktiebolag | Non-glycosylated variants of extracellular superoxide dismutase (EC-SOD) |
US5403834A (en) * | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5405369A (en) * | 1994-01-25 | 1995-04-11 | Medical College Of Ohio | Photochemical ablation of gastro-intestinal tissue for augmentation of an organ |
US5563132A (en) * | 1994-06-21 | 1996-10-08 | Bodaness; Richard S. | Two-step cancer treatment method |
US5599924A (en) * | 1992-08-14 | 1997-02-04 | Trustees Of The University Of Pennsylvania | Electron-deficient porphyrins and processes and intermediates for preparing same |
US5604199A (en) * | 1994-03-29 | 1997-02-18 | The Nemours Foundation | Method of treating fibrosis in skeletal muscle tissue |
US5610293A (en) * | 1991-07-19 | 1997-03-11 | Monsanto Company | Methods of preparing manganese complexes of nitrogen-containing macrocyclic ligands |
US5674467A (en) * | 1993-02-17 | 1997-10-07 | Institut Fur Diagnostikforschung Gmbh | Meso-tetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing the latter |
US5747026A (en) * | 1993-10-15 | 1998-05-05 | University Of Alabama At Birmingham Research Foundation | Antioxidants |
US5767272A (en) * | 1993-12-29 | 1998-06-16 | Sun Company, Inc. (R&M) | Method of preparing meso-haloalkylporphyrins |
US5793017A (en) * | 1994-12-05 | 1998-08-11 | N.G.N. Co. Ltd. | Apparatus for automatically welding tubular components of fusible resin and pipe clamping apparatus and heating apparatus used for the same |
US5834509A (en) * | 1992-12-07 | 1998-11-10 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5948771A (en) * | 1996-01-31 | 1999-09-07 | The Trustees Of Columbia University In The City Of New York | Method for treating heart failure using tetrapyrroles and metallotetrapyrroles |
US5976551A (en) * | 1991-11-15 | 1999-11-02 | Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale | Altered major histocompatibility complex (MHC) determinant and method of using the determinant |
US5976498A (en) * | 1995-08-17 | 1999-11-02 | Neumann; William L. | Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands |
US5994410A (en) * | 1995-10-26 | 1999-11-30 | National Science Council | Therapeutic use of water-soluble fullerene derivatives |
US5994339A (en) * | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
US6013241A (en) * | 1995-01-23 | 2000-01-11 | Schering Aktiengesellschaft | Use of porphyrin-complex or expanded porphyrin-complex compounds as an infarction localization diagnosticum |
US6046188A (en) * | 1995-06-07 | 2000-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US6048093A (en) * | 1994-03-30 | 2000-04-11 | Exergren Corporation | Differential radiation detector probe |
US6060467A (en) * | 1996-09-09 | 2000-05-09 | Sangstat Medical Corporation | Graft survival prolongation with porphyrins |
US6087493A (en) * | 1997-02-05 | 2000-07-11 | Regents Of The University Of Texas System | Porphyrin compounds as telomerase inhibitors |
US6103714A (en) * | 1994-09-20 | 2000-08-15 | Duke University | Oxidoreductase activity of manganic porphyrins |
US6127356A (en) * | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
US6180620B1 (en) * | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US6214817B1 (en) * | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
US6245758B1 (en) * | 1994-05-13 | 2001-06-12 | Michael K. Stern | Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor |
US20020042407A1 (en) * | 1997-11-03 | 2002-04-11 | Duke University | Substituted porphyrins |
US6372727B1 (en) * | 1999-10-13 | 2002-04-16 | Uab Research Foundation | Metalloporphyrin treatment of neurologic disease |
US20020058643A1 (en) * | 1999-07-20 | 2002-05-16 | Pharmacia & Upjohn Company | Lyophilizate of lipid complex of water insoluble porphyrins |
US6403788B1 (en) * | 2000-07-11 | 2002-06-11 | Eukarion, Inc. | Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species |
US6417182B1 (en) * | 1993-08-25 | 2002-07-09 | Anormed Inc. | Pharmaceutical compositions comprising metal complexes |
US6544975B1 (en) * | 1999-01-25 | 2003-04-08 | National Jewish Medical And Research Center | Substituted porphyrins |
US6573258B2 (en) * | 2000-09-27 | 2003-06-03 | Frontier Scientific, Inc. | Photodynamic porphyrin antimicrobial agents |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162231A (en) | 1989-10-25 | 1992-11-10 | Cole Dean A | Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung |
EP0676472A1 (en) | 1987-03-14 | 1995-10-11 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Human manganese superoxide dismutase (hMn-SOD) |
GB8805849D0 (en) | 1988-03-11 | 1988-04-13 | Efamol Holdings | Porphyrins & cancer treatment |
DE3809671A1 (en) | 1988-03-18 | 1989-09-28 | Schering Ag | PORPHYRINE COMPLEX COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM |
JPH0746212B2 (en) * | 1988-12-03 | 1995-05-17 | 工業技術院長 | Method for producing anisotropic LB film |
EP0414915B1 (en) | 1989-03-06 | 1996-06-12 | Suntory Limited | New superoxide dismutase |
JPH03273082A (en) | 1990-03-20 | 1991-12-04 | Dai Ichi Seiyaku Co Ltd | Peroxide decomposer |
EP0462836A3 (en) | 1990-06-20 | 1992-08-26 | Mitsui Toatsu Chemicals, Inc. | Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme |
AU8947791A (en) | 1990-11-01 | 1992-05-26 | Scripps Research Institute, The | Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions |
GB9103991D0 (en) | 1991-02-26 | 1991-04-10 | Nat Res Dev | Molecular electronic devices |
FR2676738B1 (en) | 1991-05-22 | 1995-05-05 | Ir2M | NOVEL ORGANIC TRANSITION METAL WITH PORPHYRINIC STRUCTURE, THERAPEUTIC COMPOSITION CONTAINING SAME, IN PARTICULAR WITH HYPOGLYCEMIC ACTIVITY. |
WO1993002090A1 (en) | 1991-07-19 | 1993-02-04 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5212300A (en) | 1991-09-12 | 1993-05-18 | Sun Company, Inc. (R&M) | Cyano- and polycyanometallo-porphyrins as catalysts for alkane oxidation |
US5371199B1 (en) | 1992-08-14 | 1995-12-26 | Univ Pennsylvania | Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor |
US5493017A (en) | 1992-08-14 | 1996-02-20 | The Trustees Of The University Of Pennsylvania | Ring-metalated porphyrins |
EP0658109B1 (en) | 1992-09-03 | 2001-05-30 | The Regents Of The University Of California | Metallo porphyrin compositions |
BR9507643A (en) | 1994-05-13 | 1997-09-23 | Monsanto Co | Methods of use for peroxynitrite decomposition catalysts pharmaceutical compositions for them |
CA2132690A1 (en) | 1994-09-22 | 1996-03-23 | Dean Willis | Control and modulation of inflammatory response in humans in need of such control and modulation |
JPH11221964A (en) * | 1998-02-09 | 1999-08-17 | Mitsubishi Chemical Corp | Optical recording medium |
WO2001040233A1 (en) | 1999-11-30 | 2001-06-07 | Photochemical Co., Ltd. | Nitroimidazole-supporting porphyrin complex |
JP3383839B2 (en) | 2000-03-13 | 2003-03-10 | 奈良先端科学技術大学院大学長 | Novel mercapto-substituted imidazolyl porphyrin metal complex monomer, polymer having the same as a repeating unit, and methods for producing them |
US6624187B1 (en) * | 2000-06-12 | 2003-09-23 | Health Research, Inc. | Long wave length absorbing bacteriochlorin alkyl ether analogs |
US6566517B2 (en) | 2001-06-06 | 2003-05-20 | Brookhaven Science Associates, Llc | Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy |
-
2003
- 2003-06-09 AU AU2003237500A patent/AU2003237500A1/en not_active Abandoned
- 2003-06-09 EP EP03736949A patent/EP1513537A4/en not_active Withdrawn
- 2003-06-09 US US10/456,956 patent/US7485721B2/en not_active Expired - Fee Related
- 2003-06-09 WO PCT/US2003/018099 patent/WO2003103680A1/en active Application Filing
- 2003-06-09 CA CA002488500A patent/CA2488500A1/en not_active Abandoned
- 2003-06-09 JP JP2004510799A patent/JP2006501163A/en active Pending
-
2008
- 2008-02-04 US US12/025,612 patent/US20080207582A1/en not_active Abandoned
Patent Citations (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2951799A (en) * | 1957-11-13 | 1960-09-06 | Monsanto Chemicals | Photoxidation processes using heterocyclic photosensitizers |
US4614723A (en) * | 1983-06-03 | 1986-09-30 | Hoffmann-La Roche Inc. | Porphyrin derivatives as fluorescent markers for immunoassays |
US4829984A (en) * | 1983-12-15 | 1989-05-16 | Gordon Robert T | Method for the improvement of transplantation techniques and for the preservation of tissue |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US5087438A (en) * | 1984-07-03 | 1992-02-11 | Gordon Robert T | Method for affecting intracellular and extracellular electric and magnetic dipoles |
US4837221A (en) * | 1984-11-26 | 1989-06-06 | Efamol Ltd. | Methods of treating tumors susceptible to necrosis |
US4758422A (en) * | 1985-01-04 | 1988-07-19 | Salutar Inc. | Ferrioxamine paramagnetic contrast agents for MR imaging |
US4657902A (en) * | 1985-03-25 | 1987-04-14 | The Rockefeller University | Therapeutic use of tin mesoporphyrin |
US4895719A (en) * | 1985-05-22 | 1990-01-23 | Liposome Technology, Inc. | Method and apparatus for administering dehydrated liposomes by inhalation |
US5472691A (en) * | 1985-09-03 | 1995-12-05 | Symbicom Aktiebolag | Superoxide dismutase |
US5130245A (en) * | 1985-09-03 | 1992-07-14 | Stefan Marklund | Superoxide dismutase |
US5248603A (en) * | 1985-09-03 | 1993-09-28 | Symbicom Aktiebolag | Superoxide dismutase |
US4866054A (en) * | 1986-05-13 | 1989-09-12 | Chai-Tech Corporation | Antioxidant metallo-organic treatment of inflammation |
US4746735A (en) * | 1986-11-21 | 1988-05-24 | The Dow Chemical Company | Regiospecific aryl nitration of meso-substituted tetraarylporphyrins |
US5227405A (en) * | 1987-03-31 | 1993-07-13 | Duke University | Superoxide dismutase mimic |
US5223538A (en) * | 1987-03-31 | 1993-06-29 | Duke University | Superoxide dismutase mimic |
US4892941A (en) * | 1987-04-17 | 1990-01-09 | Dolphin David H | Porphyrins |
US4851403A (en) * | 1987-04-21 | 1989-07-25 | Johnson Matthey, Inc. | Radiation sensitizers |
US4885114A (en) * | 1987-04-22 | 1989-12-05 | Barnes Engineering Co. | Metallized tetra((meso)-5-methyl-2-thiophene)porphines, platinum (5-bromo octaethylporphine) and optical filters containing same |
US5051337A (en) * | 1987-06-10 | 1991-09-24 | Director-General Of Agency Of Industrial Science And Technology | Optical recording material |
US5162519A (en) * | 1988-03-11 | 1992-11-10 | Efamol Holdings Plc | Porphyrins and cancer treatment |
US5284647A (en) * | 1988-03-18 | 1994-02-08 | Schering Aktiengesellschaft | Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them |
US5109016A (en) * | 1988-05-23 | 1992-04-28 | Georgia State University Foundation, Inc. | Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions |
US5192788A (en) * | 1988-05-23 | 1993-03-09 | Georgia State University Foundation, Inc. | Porphyrin antiviral compositions |
US5281616A (en) * | 1988-05-23 | 1994-01-25 | Georgia State University Foundation, Inc. | Porphyrin and phthalocyanine antiviral compositions |
US5236914A (en) * | 1988-06-02 | 1993-08-17 | Centre National De La Recherche Scientifique (Cnrs) | Derivatives of metalloporphyrins and application thereof for therapeutic purposes and in preparing hybrid molecules |
US5171680A (en) * | 1988-06-14 | 1992-12-15 | Chiron Corporation | Superoxide dismutase analogs having novel binding properties |
US5366729A (en) * | 1989-09-15 | 1994-11-22 | Symbicom Aktiebolag | Non-glycosylated variants of extracellular superoxide dismutase (EC-SOD) |
US5010073A (en) * | 1989-10-05 | 1991-04-23 | The Rockefeller University | Use of liposomes as carriers for metalloporphyrins |
US5169630A (en) * | 1989-10-19 | 1992-12-08 | Pola Chemical Industries, Ltd. | External skin preparation |
US5236915A (en) * | 1990-05-31 | 1993-08-17 | Health Research, Inc. | Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing agents |
US5202317A (en) * | 1990-09-13 | 1993-04-13 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
US5217966A (en) * | 1990-09-13 | 1993-06-08 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
US5277908A (en) * | 1990-11-14 | 1994-01-11 | The Uab Research Foundation | Modified superoxide dismutase |
US5192757A (en) * | 1990-12-20 | 1993-03-09 | Glaxo Inc. | Cobalt porphyrins |
US5874421A (en) * | 1991-07-19 | 1999-02-23 | G. D. Searle & Co. | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5610293A (en) * | 1991-07-19 | 1997-03-11 | Monsanto Company | Methods of preparing manganese complexes of nitrogen-containing macrocyclic ligands |
US5637578A (en) * | 1991-07-19 | 1997-06-10 | Riley; Dennis P. | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5262532A (en) * | 1991-07-22 | 1993-11-16 | E.R. Squibb & Sons, Inc. | Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging |
US5976551A (en) * | 1991-11-15 | 1999-11-02 | Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale | Altered major histocompatibility complex (MHC) determinant and method of using the determinant |
US5599924A (en) * | 1992-08-14 | 1997-02-04 | Trustees Of The University Of Pennsylvania | Electron-deficient porphyrins and processes and intermediates for preparing same |
US5403834A (en) * | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5834509A (en) * | 1992-12-07 | 1998-11-10 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5674467A (en) * | 1993-02-17 | 1997-10-07 | Institut Fur Diagnostikforschung Gmbh | Meso-tetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing the latter |
US6417182B1 (en) * | 1993-08-25 | 2002-07-09 | Anormed Inc. | Pharmaceutical compositions comprising metal complexes |
US6127356A (en) * | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
US5747026A (en) * | 1993-10-15 | 1998-05-05 | University Of Alabama At Birmingham Research Foundation | Antioxidants |
US5994339A (en) * | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
US5767272A (en) * | 1993-12-29 | 1998-06-16 | Sun Company, Inc. (R&M) | Method of preparing meso-haloalkylporphyrins |
US5405369A (en) * | 1994-01-25 | 1995-04-11 | Medical College Of Ohio | Photochemical ablation of gastro-intestinal tissue for augmentation of an organ |
US5604199A (en) * | 1994-03-29 | 1997-02-18 | The Nemours Foundation | Method of treating fibrosis in skeletal muscle tissue |
US6048093A (en) * | 1994-03-30 | 2000-04-11 | Exergren Corporation | Differential radiation detector probe |
US6245758B1 (en) * | 1994-05-13 | 2001-06-12 | Michael K. Stern | Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor |
US5563132A (en) * | 1994-06-21 | 1996-10-08 | Bodaness; Richard S. | Two-step cancer treatment method |
US6103714A (en) * | 1994-09-20 | 2000-08-15 | Duke University | Oxidoreductase activity of manganic porphyrins |
US5793017A (en) * | 1994-12-05 | 1998-08-11 | N.G.N. Co. Ltd. | Apparatus for automatically welding tubular components of fusible resin and pipe clamping apparatus and heating apparatus used for the same |
US6013241A (en) * | 1995-01-23 | 2000-01-11 | Schering Aktiengesellschaft | Use of porphyrin-complex or expanded porphyrin-complex compounds as an infarction localization diagnosticum |
US6046188A (en) * | 1995-06-07 | 2000-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5976498A (en) * | 1995-08-17 | 1999-11-02 | Neumann; William L. | Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands |
US5994410A (en) * | 1995-10-26 | 1999-11-30 | National Science Council | Therapeutic use of water-soluble fullerene derivatives |
US5948771A (en) * | 1996-01-31 | 1999-09-07 | The Trustees Of Columbia University In The City Of New York | Method for treating heart failure using tetrapyrroles and metallotetrapyrroles |
US6060467A (en) * | 1996-09-09 | 2000-05-09 | Sangstat Medical Corporation | Graft survival prolongation with porphyrins |
US6087493A (en) * | 1997-02-05 | 2000-07-11 | Regents Of The University Of Texas System | Porphyrin compounds as telomerase inhibitors |
US6180620B1 (en) * | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
US6214817B1 (en) * | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
US6395725B1 (en) * | 1997-06-20 | 2002-05-28 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
US20020042407A1 (en) * | 1997-11-03 | 2002-04-11 | Duke University | Substituted porphyrins |
US6544975B1 (en) * | 1999-01-25 | 2003-04-08 | National Jewish Medical And Research Center | Substituted porphyrins |
US20020058643A1 (en) * | 1999-07-20 | 2002-05-16 | Pharmacia & Upjohn Company | Lyophilizate of lipid complex of water insoluble porphyrins |
US6372727B1 (en) * | 1999-10-13 | 2002-04-16 | Uab Research Foundation | Metalloporphyrin treatment of neurologic disease |
US6403788B1 (en) * | 2000-07-11 | 2002-06-11 | Eukarion, Inc. | Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species |
US6573258B2 (en) * | 2000-09-27 | 2003-06-03 | Frontier Scientific, Inc. | Photodynamic porphyrin antimicrobial agents |
Also Published As
Publication number | Publication date |
---|---|
US7485721B2 (en) | 2009-02-03 |
EP1513537A4 (en) | 2006-09-06 |
AU2003237500A1 (en) | 2003-12-22 |
EP1513537A1 (en) | 2005-03-16 |
US20040058902A1 (en) | 2004-03-25 |
JP2006501163A (en) | 2006-01-12 |
WO2003103680A1 (en) | 2003-12-18 |
CA2488500A1 (en) | 2003-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Batinić-Haberle et al. | Manganese (III) meso-tetrakis (ortho-N-alkylpyridyl) porphyrins. Synthesis, characterization, and catalysis of O 2− dismutation | |
US20080207582A1 (en) | Substituted Porphyrins | |
Batinić-Haberle et al. | New class of potent catalysts of O 2˙− dismutation. Mn (iii) ortho-methoxyethylpyridyl-and di-ortho-methoxyethylimidazolylporphyrins | |
US8618089B2 (en) | Substituted porphyrins | |
Batinić-Haberle et al. | New PEG-ylated Mn (III) porphyrins approaching catalytic activity of SOD enzyme | |
Batinić-Haberle et al. | A potent superoxide dismutase mimic: manganese β-octabromo-meso-tetrakis-(N-methylpyridinium-4-yl) porphyrin | |
Rajic et al. | A new SOD mimic, Mn (III) ortho N-butoxyethylpyridylporphyrin, combines superb potency and lipophilicity with low toxicity | |
Lahaye et al. | Design and synthesis of manganese porphyrins with tailored lipophilicity: investigation of redox properties and superoxide dismutase activity | |
AU780118B2 (en) | Peroxynitrite decomposition catalysts and methods of use thereof | |
CA2309154C (en) | Substituted porphyrins | |
Tovmasyan et al. | Methoxy-derivatization of alkyl chains increases the in vivo efficacy of cationic Mn porphyrins. Synthesis, characterization, SOD-like activity, and SOD-deficient E. coli study of meta Mn (III) N-methoxyalkylpyridylporphyrins | |
Kachadourian et al. | Syntheses and Superoxide Dismuting Activities of Partially (1− 4) β-Chlorinated Derivatives of Manganese (III) m eso-Tetrakis (N-ethylpyridinium-2-yl) porphyrin | |
DeFreitas-Silva et al. | SOD-like activity of Mn (II) β-octabromo-meso-tetrakis (N-methylpyridinium-3-yl) porphyrin equals that of the enzyme itself | |
Yang et al. | β-Nitro-substituted free-base, iron (III) and manganese (III) tetraarylporphyrins: synthesis, electrochemistry and effect of the NO 2 substituent on spectra and redox potentials in non-aqueous media | |
EP1320532A1 (en) | Tetrapyrroles | |
Das et al. | Carbazole appended trans-dicationic pyridinium porphyrin finds supremacy in DNA binding/photocleavage over a non-carbazolyl analogue | |
US20040039211A1 (en) | Tetrapyrroles | |
Tovmasyan et al. | Rational design of SOD mimics | |
EP2627628B1 (en) | Novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them, and their use as inhibitors of the thioredoxin - thioredoxin reductase system | |
Murali et al. | Mixed-ligand copper (II) complexes with positive redox potentials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |